{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:19:05Z","timestamp":1697001545468},"reference-count":12,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T00:00:00Z","timestamp":1103673600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:bold>\n            <jats:italic>Background<\/jats:italic>\n          <\/jats:bold>:\u2002Arbekacin (ABK) is an aminoglycoside antibiotic that has a dose\u2010dependent bactericidal action. Because it inhibits the production of toxic shock syndrome toxin\u20101 (TSST\u20101) by methicillin\u2010resistant Staphylococcus aureus (MRSA), it has attracted attention as a therapeutic drug for MRSA infection. In this study, the authors investigated the pharmacokinetics of ABK based on therapeutic drug monitoring (TDM), in order to establish an effective dosage regimen with minimal adverse reactions in MRSA infected newborns and infants.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold>:\u2002Arbekacin was administered to nine MRSA infected newborns and infants between October 2000 and March 2002. Following the initial ABK administration, blood was collected and the blood concentration of ABK was measured. The blood concentrations of ABK were analyzed by the two\u2010compartment model or by a model\u2010independent method in order to elucidate the pharmacokinetics of ABK. Pharmacokinetic analysis was performed using WinNonlin Professional V3.1.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold>:\u2002The mean age at initial ABK administration was 24.0\u2003\u00b1\u200326.0\u2003days (postconceptional age: 39.2\u2003\u00b1\u20033.9\u2003weeks). The increase in the peak blood concentration of ABK was 2.40\u2003\u00b1\u20030.20\u2003\u00b5g\/mL per mg ABK per kg bodyweight, showing great consistency among cases. The elimination half\u2010life of ABK was 0.22\u20133.52\u2003h in the \u03b1 phase (T<jats:sub>1\/2\u03b1<\/jats:sub>) and 2.42\u201333.44\u2003h in the \u03b2 phase (T<jats:sub>1\/2\u03b2<\/jats:sub>), showing great variation among cases. The distribution volume was 0.75\u2003\u00b1\u20030.13\u2003L\/kg, and systemic clearance was 0.054\u2003\u00b1\u20030.012\u2003L\/h\/kg. ABK alleviated clinical symptoms and inflammations in all cases.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusion<\/jats:italic>\n          <\/jats:bold>:\u2002Nine newborns and infants with MRSA infection and various underlying diseases were successfully treated with TDM\u2010based administration of ABK with no severe adverse reactions.<\/jats:p>","DOI":"10.1111\/j.1442-200x.2004.01971.x","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T10:47:02Z","timestamp":1103712422000},"page":"645-649","source":"Crossref","is-referenced-by-count":1,"title":["Dosage regimen of arbekacin for methicillin\u2010resistant <i>Staphylococcus aureus<\/i> infection in newborns and infants"],"prefix":"10.1111","volume":"46","author":[{"given":"Koichi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Minowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Ebisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,12,22]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"676","article-title":"Evaluation of one\u2010daily administration of arbekacin","volume":"47","author":"Totsuka K","year":"1994","journal-title":"Jpn J. Antibiot."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200X.2003.01679.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80799-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1998.0810s2033.x"},{"key":"e_1_2_6_6_2","first-page":"57","article-title":"Clinical studies of arbekacin sulfate in the pediatric field","volume":"47","author":"Fujii R","year":"1994","journal-title":"Jpn J. Antibiot."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.4.471"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.3.594"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(98)90540-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90137-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.6.1228"},{"key":"e_1_2_6_13_2","first-page":"470","article-title":"In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats","volume":"236","author":"Giuliano RA","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-200x.2004.01971.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-200x.2004.01971.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:01:08Z","timestamp":1696921268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-200x.2004.01971.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1442-200x.2004.01971.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-200x.2004.01971.x","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}